Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04902105 · ClinicalTrials.gov registry record · Phase 1
Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite
A Phase 1 study, sponsored by Emalex Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT04902105 is a Phase 1 study that has completed, run by Emalex Biosciences. The registered enrollment target is 38 participants.
The verdict
NCT04902105, a Phase 1 study, has completed, sponsored by Emalex Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
This is a single center, open-label, fixed sequence, drug-drug interaction (DDI) study in healthy subjects.
Interventions
- DRUG Divalproex Sodium ER
- DRUG ecopipam HCL
- DRUG Mefenamic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2021-05-13 |
| Est. Completion | 2021-07-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04902105
The ClinicalTrials.gov registry entry for NCT04902105 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emalex Biosciences, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Divalproex Sodium ER is the first listed.
NCT04902105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04902105 about?
NCT04902105 is a clinical study titled "Drug-Drug Interaction Study to Evaluate the Effect of Inhibition of UGTs on the PK of Ecopipam and Its Active Metabolite". This is a single center, open-label, fixed sequence, drug-drug interaction (DDI) study in healthy subjects.
What is the current status of trial NCT04902105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2021-05-13. Estimated completion is 2021-07-06.
What interventions are being tested in trial NCT04902105?
The interventions under investigation include: Divalproex Sodium ER (DRUG), ecopipam HCL (DRUG), Mefenamic acid (DRUG).
Who is sponsoring clinical trial NCT04902105?
This trial is sponsored by Emalex Biosciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.